ALEXANDRIA, Va., Sept. 10 -- United States Patent no. 12,410,175, issued on Sept. 9, was assigned to INTRA-CELLULAR THERAPIES INC. (Bedminster, N.J.).
"Compounds" was invented by Peng Li (New Milford, N.J.) and Robert Davis (San Diego).
According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to PDE1 inhibitory compounds useful in the treatment of diseases involving disorders of the dopamine D1 receptor intracellular pathway, such as, among others, Parkinson's disease, depression, narcolepsy, psychosis, damage to cognitive function, e.g., in schizophrenia, or disorders that may be ameliorated through enhanced progesterone-signaling pathway, as well as their use as pharmaceuticals and pharma...